Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation

Journal of Experimental Medicine

Volumn 210, Issue 12, 2013, Pages 2675-2692

  Leung, Wai Hang ^a   Vong, Queenie P ^a   Lin, Wenwei ^a   Janke, Laura ^a   Chen, Taosheng ^a   Leung, Wing ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINERALOCORTICOID RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; RETINOID X RECEPTOR GAMMA; SMALL INTERFERING RNA; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER PREVENTION; CELL STRAIN HCT116; COLON CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; METASTASIS; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LIGANDS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, MINERALOCORTICOID; RETINOID X RECEPTOR GAMMA; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888113464     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20122292     Document Type: Article

References (61)

1. Albini, A., A. Melchiori, L. Santi, L.A. Liotta, P.D. Brown, and W.G. Stetler-Stevenson. 1991. Tumor cell invasion inhibited by TIMP-2. J. Natl. Cancer Inst. 83, 775-779 http://dx.doi.org/10.1093/jnci/83.11.775.
2. André, P., R. Castriconi, M. Espéli, N. Anfossi, T. Juarez, S. Hue, H. Conway, F. Romagné, A. Dondero, M. Nanni, et al. 2004. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur. J. Immunol. 34, 961-971 http://dx.doi.org/10.1002/eji.200324705.
3. Armeanu, S., M. Bitzer, U.M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, et al. 2005. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65, 6321-6329 http://dx.doi.org/10.1158/0008-5472.CAN-04-4252.
4. Bae, J.H., J.Y. Kim, M.J. Kim, S.H. Chang, Y.S. Park, C.H. Son, S.J. Park, J.S. Chung, E.Y. Lee, S.H. Kim, and C.D. Kang. 2010. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J. Immunother. 33, 391-401 http://dx.doi.org/10.1097/CJI.0b013e3181d32f22.
5. Bakkenist, C.J., and M.B. Kastan. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421, 499-506 http://dx.doi.org/10.1038/nature01368.
6. Bartek, J., and J. Lukas. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 3, 421-429 http://dx.doi.org/10.1016/S1535-6108(03)00110-7.
7. Boehm, M.F., L. Zhang, B.A. Badea, S.K. White, D.E. Mais, E. Berger, C.M. Suto, M.E. Goldman, and R.A. Heyman. 1994. Synthesis and structureactivity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem. 37, 2930-2941 http://dx.doi.org/10.1021/jm00044a014.
8. Brew, K., and H. Nagase. 2010. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta. 1803, 55-71 http://dx.doi.org/10.1016/j.bbamcr.2010.01.003.
9. Cappell, M.S. 2008. Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol. Clin. North Am. 37:1-24: v (v.). http://dx.doi.org/10.1016/j.gtc.2007.12.002
10. Champsaur, M., and L.L. Lanier. 2010. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235, 267-285.
11. Chan, W.K., M. Kung Sutherland, Y. Li, J. Zalevsky, S. Schell, and W. Leung. 2012. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Clin. Cancer Res. 18, 6296-6305 http://dx.doi.org/10.1158/1078-0432.CCR-12-0668.
12. Dawson, M.I., and Z. Xia. 2012. The retinoid X receptors and their ligands. Biochim. Biophys. Acta. 1821, 21-56 http://dx.doi.org/10.1016/j.bbalip.2011.09.014.
13. Diermayr, S., H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al. 2008. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood. 111, 1428-1436 http://dx.doi.org/10.1182/blood-2007-07-101311.
14. Dilworth, F.J., and P. Chambon. 2001. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene. 20, 3047-3054 http://dx.doi.org/10.1038/sj.onc.1204329.
15. Dunn, C., N.J. Chalupny, C.L. Sutherland, S. Dosch, P.V. Sivakumar, D.C. Johnson, and D. Cosman. 2003. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J. Exp. Med. 197, 1427-1439 http://dx.doi.org/10.1084/jem.20022059.
16. Eeckhoute, J., F. Oger, B. Staels, and P. Lefebvre. 2012. Coordinated Regulation of PPAR? Expression and Activity through Control of Chromatin Structure in Adipogenesis and Obesity. PPAR Res. 2012:164140. http://dx.doi.org/10.1155/2012/164140
17. Fuertes, M.B., M.V. Girart, L.L. Molinero, C.I. Domaica, L.E. Rossi, M.M. Barrio, J. Mordoh, G.A. Rabinovich, and N.W. Zwirner. 2008. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J. Immunol. 180, 4606-4614.
18. Fujisaki, H., H. Kakuda, N. Shimasaki, C. Imai, J. Ma, T. Lockey, P. Eldridge, W.H. Leung, and D. Campana. 2009. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 69, 4010-4017 http://dx.doi.org/10.1158/0008-5472.CAN-08-3712.
19. Gasser, S., S. Orsulic, E.J. Brown, and D.H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 436, 1186-1190 http://dx.doi.org/10.1038/nature03884.
20. González, S., A. López-Soto, B. Suarez-Alvarez, A. López-Vázquez, and C. López-Larrea. 2008. NKG2D ligands: key targets of the immune response. Trends Immunol. 29, 397-403 http://dx.doi.org/10.1016/j.it.2008.04.007.
21. Groh, V., S. Bahram, S. Bauer, A. Herman, M. Beauchamp, and T. Spies. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA. 93, 12445-12450 http://dx.doi.org/10.1073/pnas.93.22.12445.
22. Guo, Z., S. Kozlov, M.F. Lavin, M.D. Person, and T.T. Paull. 2010. ATM activation by oxidative stress. Science. 330, 517-521 http://dx.doi.org/10.1126/science.1192912.
23. Gupta, A., G.G. Sharma, C.S. Young, M. Agarwal, E.R. Smith, T.T. Paull, J.C. Lucchesi, K.K. Khanna, T. Ludwig, and T.K. Pandita. 2005. Involvement of human MOF in ATM function. Mol. Cell. Biol. 25, 5292-5305 http://dx.doi.org/10.1128/MCB.25.12.5292-5305.2005.
24. Hamada, K., M. Monnai, K. Kawai, C. Nishime, C. Kito, N. Miyazaki, Y. Ohnishi, M. Nakamura, and H. Suemizu. 2008. Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice. Int. J. Oncol. 32, 153-159.
25. Huang, J.K., A.A. Jarjour, B. Nait Oumesmar, C. Kerninon, A. Williams, W. Krezel, H. Kagechika, J. Bauer, C. Zhao, A. Baron-Van Evercooren, et al. 2011. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat. Neurosci. 14, 45-53 http://dx.doi.org/10.1038/nn.2702.
26. Hunt, C.R., R.K. Pandita, A. Laszlo, R. Higashikubo, M. Agarwal, T. Kitamura, A. Gupta, N. Rief, N. Horikoshi, R. Baskaran, et al. 2007. Hyperthermia activates a subset of ataxia-telangiectasia mutated effectors independent of DNA strand breaks and heat shock protein 70 status. Cancer Res. 67, 3010-3017 http://dx.doi.org/10.1158/0008-5472. CAN-06-4328.
27. Jojovic, M., and U. Schumacher. 2000. Quantitative assessment of spontaneous lung metastases of human HT29 colon cancer cells transplanted into SCID mice. Cancer Lett. 152, 151-156 http://dx.doi.org/10.1016/S0304-3835(99)00443-7.
28. Kastan, M.B., and D.S. Lim. 2000. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1, 179-186 http://dx.doi.org/10.1038/35043058.
29. Lai, M., E.S. Zimmerman, V. Planelles, and J. Chen. 2005. Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J. Virol. 79, 15443-15451 http://dx.doi.org/10.1128/JVI.79.24.15443-15451.2005.
30. Ljunggren, H.G., and K.J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329-339 http://dx.doi.org/10.1038/nri2073.
31. Loging, W.T., and D. Reisman. 1999. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. Oncogene. 18, 7608-7615 http://dx.doi.org/10.1038/sj.onc.1203135.
32. López-Soto, A., A.R. Folgueras, E. Seto, and S. Gonzalez. 2009. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene. 28, 2370-2382 http://dx.doi.org/10.1038/onc.2009.117.
33. Malemud, C.J. 2006a. Matrix metalloproteinases (MMPs) in health and disease:an overview. Front. Biosci. 11:1696-1701. http://dx.doi.org/10.2741/1915
34. Malemud, C.J. 2006b. Matrix metalloproteinases: role in skeletal development and growth plate disorders. Front. Biosci. 11:1702-1715. http://dx.doi.org/10.2741/1916
35. McGilvray, R.W., R.A. Eagle, N.F. Watson, A. Al-Attar, G. Ball, I. Jafferji, J. Trowsdale, and L.G. Durrant. 2009. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin. Cancer Res. 15, 6993-7002 http://dx.doi.org/10.1158/1078-0432.CCR-09-0991.
36. Messerli, F.H. 2004. TIMPs, MMPs and cardiovascular disease. Eur. Heart J. 25, 1475-1476 http://dx.doi.org/10.1016/j.ehj.2004.07.015.
37. Murray, G.I., M.E. Duncan, P. O'Neil, W.T. Melvin, and J.E. Fothergill. 1996. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2, 461-462 http://dx.doi.org/10.1038/nm0496-461.
38. Nausch, N., and A. Cerwenka. 2008. NKG2D ligands in tumor immunity. Oncogene. 27, 5944-5958 http://dx.doi.org/10.1038/onc.2008.272.
39. Papi, A., P. Rocchi, A.M. Ferreri, and M. Orlandi. 2010. RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells. Cancer Lett. 297, 65-74 http://dx.doi.org/10.1016/j.canlet.2010.04.026.
40. Pulukuri, S.M., and J.S. Rao. 2008. Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int. J. Oncol. 32, 757-765.
41. Ring, P., K. Johansson, M. Höyhtyä, K. Rubin, and G. Lindmark. 1997. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage. Br. J. Cancer. 76, 805-811 http://dx.doi.org/10.1038/bjc.1997.466.
42. Rujkijyanont, P., W.K. Chan, P.W. Eldridge, T. Lockey, M. Holladay, B. Rooney, A.M. Davidoff, W. Leung, and Q. Vong. 2013. Ex vivo activation of CD56(+) immune cells that eradicate neuroblastoma. Cancer Res. 73, 2608-2618 http://dx.doi.org/10.1158/0008-5472.CAN-12-3322.
43. Salih, H.R., H.G. Rammensee, and A. Steinle. 2002. Cutting edge: downregulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169, 4098-4102.
44. Schou, K.B., L. Schneider, S.T. Christensen, and E.K. Hoffmann. 2008. Earlystage apoptosis is associated with DNA-damage-independent ATM phosphorylation and chromatin decondensation in NIH3T3 fibroblasts. Cell Biol. Int. 32, 107-113 http://dx.doi.org/10.1016/j.cellbi.2007.08.019.
45. Schupp, N., P. Kolkhof, N. Queisser, S. Gärtner, U. Schmid, A. Kretschmer, E. Hartmann, R.G. Oli, S. Schäfer, and H. Stopper. 2011a. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J. 25:968-978. http://dx.doi.org/10.1096/fj.10-173286
46. Schupp, N., N. Queisser, M. Wolf, P. Kolkhof, L. Bärfacker, S. Schäfer, A. Heidland, and H. Stopper. 2010b. Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists. Horm. Metab. Res. 42:458-465. http://dx.doi.org/10.1055/s-0029-1243253
47. Shen, K., Y. Wang, S.C. Brooks, A. Raz, and Y.A. Wang. 2006. ATM is activated by mitotic stress and suppresses centrosome amplification in primary but not in tumor cells. J. Cell. Biochem. 99, 1267-1274 http://dx.doi.org/10.1002/jcb.20848.
48. Shiloh, Y. 2003. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer. 3, 155-168 http://dx.doi.org/10.1038/nrc1011.
49. Siersbæk, R., R. Nielsen, S. John, M.H. Sung, S. Baek, A. Loft, G.L. Hager, and S. Mandrup. 2011. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. EMBO J. 30, 1459-1472 http://dx.doi.org/10.1038/emboj.2011.65.
50. Song, B., C. Wang, J. Liu, X. Wang, L. Lv, L. Wei, L. Xie, Y. Zheng, and X. Song. 2010. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J. Exp. Clin. Cancer Res. 29:29. http://dx.doi.org/10.1186/1756-9966-29-29
51. Soriani, A., A. Zingoni, C. Cerboni, M.L. Iannitto, M.R. Ricciardi, V. Di Gialleonardo, M. Cippitelli, C. Fionda, M.T. Petrucci, A. Guarini, et al. 2009. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 113, 3503-3511 http://dx.doi.org/10.1182/blood-2008-08-173914.
52. Stern-Ginossar, N., C. Gur, M. Biton, E. Horwitz, M. Elboim, N. Stanietsky, M. Mandelboim, and O. Mandelboim. 2008. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat. Immunol. 9, 1065-1073 http://dx.doi.org/10.1038/ni.1642.
53. Struthers, A., H. Krum, and G.H. Williams. 2008. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin. Cardiol. 31, 153-158 http://dx.doi.org/10.1002/clc.20324.
54. Su, L.K., K.W. Kinzler, B. Vogelstein, A.C. Preisinger, A.R. Moser, C. Luongo, K.A. Gould, and W.F. Dove. 1992. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 256, 668-670 http://dx.doi.org/10.1126/science.1350108.
55. Sunami, E., N. Tsuno, T. Osada, S. Saito, J. Kitayama, S. Tomozawa, T. Tsuruo, Y. Shibata, T. Muto, and H. Nagawa. 2000. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist. 5, 108-114 http://dx.doi.org/10.1634/theoncologist.5-2-108.
56. Valés-Gómez, M., S.E. Chisholm, R.L. Cassady-Cain, P. Roda-Navarro, and H.T. Reyburn. 2008. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 68, 1546-1554 http://dx.doi.org/10.1158/0008-5472.CAN-07-2973.
57. Visse, R., and H. Nagase. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839 http://dx.doi.org/10.1161/01.RES.0000070112.80711.3D.
58. Waldhauer, I., and A. Steinle. 2006. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 66, 2520-2526 http://dx.doi.org/10.1158/0008-5472.CAN-05-2520.
59. Waldhauer, I., D. Goehlsdorf, F. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H.G. Rammensee, and A. Steinle. 2008. Tumorassociated MICA is shed by ADAM proteases. Cancer Res. 68, 6368-6376 http://dx.doi.org/10.1158/0008-5472.CAN-07-6768.
60. Williams, T.A., A. Verhovez, A. Milan, F. Veglio, and P. Mulatero. 2006. Protective effect of spironolactone on endothelial cell apoptosis. Endocrinology. 147, 2496-2505 http://dx.doi.org/10.1210/en.2005-1318.
61. Yamamoto, K., Y. Fujiyama, A. Andoh, T. Bamba, and H. Okabe. 2001. Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biochim. Biophys. Acta. 1526, 10-12 http://dx.doi.org/10.1016/S0304-4165(01)00099-X.